Cargando…

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision

BACKGROUND: There is uncertainty on the benefit of adjuvant chemotherapy in patients with stage II colorectal cancers. The aim of this study is to investigate the combined role of clinical, pathological and molecular parameters to identify those stage II patients who better benefit from adjuvant the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donada, Marisa, Bonin, Serena, Barbazza, Renzo, Pettirosso, Daniel, Stanta, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599045/ https://www.ncbi.nlm.nih.gov/pubmed/23446022 http://dx.doi.org/10.1186/1471-230X-13-36

Ejemplares similares

Are Breast Cancer Molecular Classes Predictive of Survival in Patients with Long Follow-Up?
por: Pracella, Danae, et al.
Publicado: (2013)

Is Human Papillomavirus Associated with Prostate Cancer Survival?
por: Pascale, Mariarosa, et al.
Publicado: (2013)

Reduced expression of α-L-Fucosidase-1 (FUCA-1) predicts recurrence and shorter cancer specific survival in luminal B LN+ breast cancer patients
por: Bonin, Serena, et al.
Publicado: (2018)

PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement
por: Bonin, S., et al.
Publicado: (2019)

The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients
por: Pascale, Mariarosa, et al.
Publicado: (2016)

Overview on Clinical Relevance of Intra-Tumor Heterogeneity
por: Stanta, Giorgio, et al.
Publicado: (2018)

AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization
por: Azzalini, Eros, et al.
Publicado: (2022)

Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?
por: Bonin, Serena
Publicado: (2015)

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
por: Azzalini, Eros, et al.
Publicado: (2023)

Adjuvant Chemotherapy for Stage II Colon Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2020)

Reliability of miRNA Analysis from Fixed and Paraffin-Embedded Tissues
por: Azzalini, Eros, et al.
Publicado: (2019)

Adjuvant chemotherapy for stage II colon cancer: who really needs it
por: Yang, Yan, et al.
Publicado: (2018)

Circulating Tumour DNA Guided Adjuvant Chemotherapy Decision Making in Stage II Colon Cancer—A Clinical Vignette Study
por: To, Yat Hang, et al.
Publicado: (2023)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

A Novel HPLC-Based Method to Investigate on RNA after Fixation
por: Fattorini, Paolo, et al.
Publicado: (2020)

Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer
por: Jee, Sun Hee, et al.
Publicado: (2011)

Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data
por: Kim, Min Ki, et al.
Publicado: (2018)

Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa
por: Tan, Sarah Xinhui, et al.
Publicado: (2023)

Mycosis fungoides: is it a Borrelia burgdorferi-associated disease?
por: Tothova, S Miertusova, et al.
Publicado: (2006)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Adjuvant chemotherapy does not provide survival benefits to elderly patients with stage II colon cancer
por: Lee, Kil-yong, et al.
Publicado: (2019)

Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
por: Batra, Atul, et al.
Publicado: (2020)

Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer
por: Cho, Jung Rae, et al.
Publicado: (2022)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

Prevalence of Different Subtypes of Serrated Polyps and Risk of Synchronous Advanced Colorectal Neoplasia in Average-Risk Population Undergoing First-Time Colonoscopy
por: Buda, Andrea, et al.
Publicado: (2012)

Immunohistochemistry‐Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer
por: Li, Yaqi, et al.
Publicado: (2020)

Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
por: Taal, B G, et al.
Publicado: (2001)

Adjuvant Chemotherapy and Tumor Sidedness in Stage II Colon Cancer: Analysis of the National Cancer Data Base
por: Mukkamalla, Shiva Kumar R., et al.
Publicado: (2020)

Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review
por: To, Yat Hang, et al.
Publicado: (2023)

Involvement in Chemotherapy Decision Making among Patients with Stage II and III Colon Cancer
por: Austin, Jessica D., et al.
Publicado: (2023)

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer
por: Dunne, Philip D., et al.
Publicado: (2018)

High Expression of CUL9 Is Prognostic and Predictive for Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer
por: Zheng, Peng, et al.
Publicado: (2022)

Considering adjuvant therapy for stage II melanoma
por: Poklepovic, Andrew S., et al.
Publicado: (2019)

Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer
por: Yang, Lin, et al.
Publicado: (2017)

Adjuvant chemotherapy improves survival in high-risk stage II colon cancer: a retrospective cohort study
por: Liu, Lin-Lin, et al.
Publicado: (2022)

Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
por: Zunder, Stéphanie M., et al.
Publicado: (2018)

Erratum to “Involvement in Chemotherapy Decision Making among Patients with Stage II and III Colon Cancer”
Publicado: (2023)

Prognostic and Predictive Model for Stage II Colon Cancer Patients With Nonemergent Surgery: Who Should Receive Adjuvant Chemotherapy?
por: Zhang, Chun-Dong, et al.
Publicado: (2016)

Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data
por: Amlani, Adam, et al.
Publicado: (2016)

Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients
por: Oki, Eiji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i3m1o3pifbroqj56hurko853ke